Changing the Course of Patient Outcomes in Non-Small-Cell Lung Cancer: Novel Therapeutic Approaches for Early-Stage Disease

Download All
In this comprehensive program for oncology professionals, learn how the experts are leveraging emerging data on immunotherapy-based approaches for neoadjuvant and adjuvant treatment of early-stage NSCLC, including concise text-based modules from multidisciplinary perspectives, an on-demand webcast capturing a live CCO community workshop, downloadable slidesets, and a clinical resource PDF to facilitate shared-decision making with your patients.
person default
Patrick Forde, MB BCh
Stefanie L. Houseknecht, PharmD, BCOP
person default
Jonathan Spicer, MD, PhD, FRCS

Microlearning Activities with Downloadable Slidesets

In this module, a medical oncologist shares his expert perspective on emerging immunotherapy strategies in the neoadjuvant and adjuvant settings for the treatment of resectable early-stage NSCLC.

person default Patrick Forde, MB BCh Physicians: maximum of 0.75 AMA PRA Category 1 Credits Registered Nurses: 0.75 Nursing contact hours Pharmacists: 0.75 contact hours (0.075 CEUs) Released: August 26, 2021 Expired: No longer available for credit

Download this slideset to review key data on the use of immune checkpoint inhibitors as neoadjuvant and adjuvant therapy for resectable early-stage NSCLC.

person default Patrick Forde, MB BCh Released: August 26, 2021

In this module, a pharmacist shares her perspective on monitoring for and managing toxicities associated with emerging immunotherapy strategies in the neoadjuvant and adjuvant settings for the treatment of resectable early-stage NSCLC.

Stefanie L. Houseknecht, PharmD, BCOP Physicians: maximum of 0.75 AMA PRA Category 1 Credits Registered Nurses: 0.75 Nursing contact hours Pharmacists: 0.75 contact hours (0.075 CEUs) Released: October 13, 2021 Expired: No longer available for credit

Download this slideset presenting a pharmacist perspective on key data and toxicity management strategies for optimal use of immune checkpoint inhibitors as neoadjuvant and adjuvant therapy for resectable early-stage NSCLC.

Stefanie L. Houseknecht, PharmD, BCOP Released: October 13, 2021

In this module, a surgeon shares his expert perspective on the use of neoadjuvant immune checkpoint inhibitor–based therapy in resectable early-stage NSCLC.

person default Jonathan Spicer, MD, PhD, FRCS Physicians: maximum of 0.75 AMA PRA Category 1 Credits Registered Nurses: 0.75 Nursing contact hours Pharmacists: 0.75 contact hours (0.075 CEUs) Released: December 1, 2021 Expired: No longer available for credit

Download this slideset to review key data on the use of neoadjuvant immune checkpoint inhibitor–based therapy in resectable early-stage NSCLC from a surgeon’s perspective.

Released: December 1, 2021
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Genentech, a member of the Roche Group

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings